Bacteriophage-Based Vaccines and Engineered Bacteriophage
AssigneeAthanor Biosciences, Inc.
InventorsHossein A. Ghanbari, Michael S. Lebowitz
Life of this patent
Estimating the term…
Abstract
Engineered bacteriophage and methods of forming the bacteriophage are described. Multivalent bacteriophage are described that can include multiple different exogenous polypeptides at a surface of the capsid head. Vaccines and methods of forming and using vaccines are described. A vaccine can include an engineered bacteriophage that exhibits an immunogenic exogenous polypeptide at a surface of the bacteriophage. Multivalent bacteriophage and immunogenic bacteriophage are free of nucleic acids encoding the exogenous polypeptide(s).
Claims21
An engineered bacteriophage comprising:
- a first fusion coat protein comprising a first exogenous polypeptide directly or indirectly fused to a first coat protein of a bacteriophage;
- and
- a second fusion coat protein comprising a second exogenous polypeptide directly or indirectly fused to a second coat protein of the bacteriophage;
- wherein
- the engineered bacteriophage is free of nucleic acid sequences encoding the first exogenous polypeptide and the second exogenous polypeptide;
- and wherein
- the first exogenous polypeptide differs from the second exogenous polypeptide and/or the first coat protein differs from the second coat protein.
A method for forming an engineered bacteriophage, the method comprising:
- transfecting a bacterial cell with one or more expression plasmids, the one or more expression plasmids including a first nucleic acid sequence that encodes a first fusion coat protein and a second nucleic acid sequence that encodes a second fusion coat protein, the first fusion coat protein including a first exogenous polypeptide directly or indirectly fused to a first coat protein and the second fusion coat protein including a second exogenous polypeptide directly or indirectly fused to a second coat protein, the one or more expression plasmids comprising regulatory sequences such that the first and second fusion coat proteins are transiently expressed by the bacterial cell following the transfection;
- and
- infecting the bacterial cell with a bacteriophage;
- wherein
- the first exogenous polypeptide differs from the second exogenous polypeptide and/or the first coat protein differs from the second coat protein;
- and wherein
- upon the transfection and the infection, the engineered bacteriophage is produced by the bacterial cell, the engineered bacteriophage including the first fusion coat protein and the second fusion coat protein with the first and second exogenous polypeptides at a surface of the bacteriophage;
- and wherein
- the engineered bacteriophage is free of nucleic acid sequences encoding the first exogenous polypeptide and the second exogenous polypeptide.
A vaccine comprising an immunogenic engineered bacteriophage, the immunogenic engineered bacteriophage including a first fusion coat protein, the first fusion coat protein including a first exogenous polypeptide directly or indirectly fused to a first bacteriophage coat protein, the first exogenous polypeptide comprising a sequence that corresponds to or is derived from a first immunogenic protein of a first pathogen, wherein the immunogenic engineered bacteriophage is free of a nucleic acid sequence encoding the first exogenous peptide.
Dependencies are inferred from the claim text.